Targeted Lung Cancer Delivery Using Tiny Lipid‑Coated MOF Carriers

A new approach to lung cancer treatment uses a tiny metal‑organic framework (MOF) wrapped in lipids to carry the drug anlotinib directly to tumor cells. The MOF, called MIL‑101(Fe), is engineered to be very small so it can circulate in the bloodstream without getting trapped in healthy tissues. Scientists coat this MOF with a liposome layer, creating a composite called Anlo@MOF‑Lipo (AML).The liposome shell shields the drug and helps it fuse with cancer cells, releasing anlotinib where it can inhibit multiple tyrosine kinases involved in tumor growth. Preliminary tests show that AML delivers higher drug concentrations to lung tumors while reducing exposure to normal organs. This targeted strategy could lower side effects and improve the effectiveness of anlotinib therapy. Researchers plan to test AML in animal models next, aiming to confirm its safety and therapeutic benefit before moving toward clinical trials.